The Cannabis Conference 2025 was a great success – featuring exciting presentations, leading industry experts, and intensive professional exchange. We extend our thanks to all participants – especially our speakers for their committed contributions and inspiring insights.

The consistently positive feedback from attendees confirms that the event struck a chord within the industry.

As soon as new, relevant topics emerge, we will plan another event – because the dialogue continues. Stay informed! Use our non-binding reminder service to receive notifications as soon as the next conference is announced. This way, you can secure your spot early and benefit from the exclusive early-bird offer.

Register your interest now

In Europe, cannabis-based medicines are prescribed and dispensed as magistral formulations for patients or, in some member states, they can be prescribed for specific indications based on special licences. Sativex® is the only cannabis-based medicinal product with a regular marketing authorisation in Europe. This situation is certainly only temporary, and in the next few years further regularly authorised cannabis-based medicinal products will come onto the market. These products are ”herbal medicinal products”, for which there are a number of specific requirements in Europe.

The active constituents used as API in the preparations are present as multicomponent mixtures, mostly as extracts. This has implications for non-clinical and clinical development and specifically for CMC aspects. The focus here lies on ensuring batch-compliant traceability for the preparations to non-clinical and clinical batches, and a number of particularities arise that must be taken into account in non-clinical and clinical investigations.

Furthermore, there is always a risk of comparing ‘apples with oranges’ when referring to bibliographic data that may have been obtained with preparations that have different patterns of constituents than the preparation to be developed and authorised. This also applies to ”real world evidence” and ”real world data”. Finally, there are special considerations regarding the possibilities of data exclusivity and the establishment of IP protection. For products for nasal or inhaled administration, which can be useful for a rapid onset of action in acute situations, the particularities for combination products must be taken into account.